HC Wainwright upgraded shares of Vor Biopharma (NASDAQ:VOR - Free Report) from a hold rating to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports.
Separately, Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a research report on Saturday.
Check Out Our Latest Stock Analysis on VOR
Vor Biopharma Trading Up 1.4%
Shares of VOR traded up $0.02 during trading hours on Monday, reaching $1.45. The stock had a trading volume of 25,211,492 shares, compared to its average volume of 38,231,892. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $2.04.
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
See Also
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
